SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 75.22 |
| Enterprise Value ($M) | 66.29 |
| Book Value ($M) | 46.22 |
| Book Value / Share | 1.83 |
| Price / Book | 1.63 |
| NCAV ($M) | 40.36 |
| NCAV / Share | 1.59 |
| Price / NCAV | 1.86 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.07 |
| Return on Assets (ROA) | -0.55 |
| Return on Equity (ROE) | -0.86 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.40 |
| Current Ratio | 4.40 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 117.67 |
| Assets | 123.54 |
| Liabilities | 77.32 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -92.08 |
| Net Income | -87.37 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -86.46 |
| Cash from Investing | -44.45 |
| Cash from Financing | 134.19 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Biotechnology Value Fund L P | 9.99 | ||
| 13G/A | Orbimed Advisors Llc | 6.10 | ||
| 13G/A | Viking Global Investors Lp | 9.99 | 91.71 | |
| 13G/A | Vivo Opportunity, LLC | 6.10 | ||
| 13G/A | Soleus Capital Master Fund, L.P. | 6.80 | 9.89 | |
| 13G | Adage Capital Partners Gp, L.l.c. | 5.15 | ||
| 13G/A | Baker Bros. Advisors Lp | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES | ||
| UNITED STATES | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 141,359 | 814,164 | 17.36 | |
| 55,159 | 490,423 | 11.25 | |
| 312,036 | 2,048,491 | 15.23 | |
| 40,226 | 259,435 | 15.51 | |
| 73,845 | 222,864 | 33.13 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| VIRI – Virios Therapeutics, Inc. | VKTX – Viking Therapeutics, Inc. |
| VRPX – Virpax Pharmaceuticals, Inc. | VTGN – Vistagen Therapeutics, Inc. |
| VTVT – vTv Therapeutics Inc. |